AHG (Akso Health Group) YoY EBITDA Growth: 50.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AHG Akso Health Group AHG
37 GF Score
Price $0.78
GF Value $0.39
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Akso Health Group YoY EBITDA Growth?

Akso Health Group AHG -2.74% 37 YoY EBITDA Growth is 50.00% as of Mar. 2026. GuruFocus rates AHG with a GF Score™ of 37/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Akso Health Group's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 50.00%.

Akso Health Group's EBITDA per Share for the six months ended in Mar. 2026 was $-0.00.

Akso Health Group YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Akso Health Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akso Health Group YoY EBITDA Growth Chart

Akso Health Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.90 -287.58 70.67 96.72 66.67

Akso Health Group Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.00 98.02 90.70 100.00 50.00
AHG
37GF Score
Akso Health Group AHG
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akso Health Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Akso Health Group's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(-0.002--0.006)/ | -0.006 |
=66.67 %

Akso Health Group's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.002--0.004)/ | -0.004 |
=50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 50.00% mean?
Akso Health Group (AHG) has a YoY EBITDA Growth of 50.00% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Akso Health Group and its competitors.
Is Akso Health Group's YoY EBITDA Growth too high?
Akso Health Group's current YoY EBITDA Growth is 50.00%. Overall, Akso Health Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Akso Health Group's YoY EBITDA Growth compare to FOCL and ACH?
Akso Health Group's YoY EBITDA Growth of 50.00% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Distribution company?
A good YoY EBITDA Growth depends on the Medical Distribution industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Akso Health Group and its competitors. Akso Health Group's current YoY EBITDA Growth is 50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akso Health Group stock overvalued right now?
Based on GuruFocus' analysis, Akso Health Group (AHG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $0.78 — trading 99.9% above its estimated fair value. The current YoY EBITDA Growth is 50.00%. Akso Health Group's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Akso Health Group (AHG), the current YoY EBITDA Growth is 50.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akso Health Group (AHG) Overvalued in 2026?

Based on GuruFocus' analysis, Akso Health Group stock appears to be overvalued. The current stock price of $0.78 is trading 99.9% above its estimated GF Value™ of $0.39. GuruFocus considers Akso Health Group to be Significantly Overvalued.

Key valuation signals for AHG:

  • YoY EBITDA Growth: 50.00%
  • GF Value™: $0.39 vs. price of $0.78 (99.9% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the AHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akso Health Group Business Description

Other Exchanges 8HX:Germany
Address No. 44, Moscow Road, Qianwan Bonded Port Area, Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building, Qingdao Pilot Free Trade Zone, Shandong, CHN
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
37GF Score

Get the complete analysis for AHG

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.78
Price
$0.39
GF Value